Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver.

Abstract

BACKGROUND & AIMS:

Nonalcoholic steatohepatitis (NASH) is commonly observed in patients with type 2 diabetes, and thiazolidinediones (TZD) are considered a potential therapy for NASH. Although TZD increase insulin sensitivity and partially reduce steatosis and alanine aminotransferase, the efficacy of TZD on resolving liver pathology is limited. In fact, TZD may activate peroxisome proliferator-activated receptor gamma (PPARγ) in hepatocytes and promote steatosis. Therefore, we assessed the role that hepatocyte-specific PPARγ plays in the development of NASH, and how it alters the therapeutic effects of TZD on the liver of mice with diet-induced NASH.

METHODS:

Hepatocyte-specific PPARγ expression was knocked out in adult mice before and after the development of NASH induced with a high fat, cholesterol, and fructose (HFCF) diet.

RESULTS:

HFCF diet increased PPARγ expression in hepatocytes, and rosiglitazone further activated PPARγ in hepatocytes of HFCF-fed mice in vivo and in vitro. Hepatocyte-specific loss of PPARγ reduced the progression of HFCF-induced NASH in male mice and increased the benefits derived from the effects of TZD on extrahepatic tissues and non-parenchymal cells. RNAseq and metabolomics indicated that HFCF diet promoted inflammation and fibrogenesis in a hepatocyte PPARγ-dependent manner and was associated with dysregulation of hepatic metabolism. Specifically, hepatocyte-specific loss of PPARγ plays a positive role in the regulation of methionine metabolism, and that could reduce the progression of NASH.

CONCLUSIONS:

Because of the negative effect of hepatocyte PPARγ in NASH, inhibition of mechanisms promoted by endogenous PPARγ in hepatocytes may represent a novel strategy that increases the efficiency of therapies for NAFLD.

• Authors: Samuel M Lee, Carolina M Pusec, Gregory H Norris, Adam De Jesus, Alberto Diaz-Ruiz, Jose Muratalla, Andre Sarmento-Cabral, Grace Guzman, Brian T Layden, Jose Cordoba-Chacon
• Journal: Cellular and molecular gastroenterology and hepatology (Cell Mol Gastroenterol Hepatol) Vol. 11 Issue 5 Pg. 1291-1311 ( 2021) ISSN: 2352-345X [Electronic] United States
• PMID: 33444819 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Hypoglycemic Agents
• PPAR gamma
• Rosiglitazone

Topics

• Animals
• Diet, High-Fat
• Female
• Hepatocytes (drug effects, metabolism)
• Hypoglycemic Agents (pharmacology)
• Inflammation (etiology, metabolism, pathology, prevention & control)
• Male
• Mice
• Mice, Knockout
• Non-alcoholic Fatty Liver Disease (etiology, metabolism, pathology, prevention & control)
• PPAR gamma (antagonists & inhibitors, physiology)
• Rosiglitazone (pharmacology)